Pharmacometric estimation methods for aggregate data, including data simulated from other pharmacometric models

Journal of Pharmacokinetics and Pharmacodynamics - Tập 48 Số 5 - Trang 623-638 - 2021
Pyry A. J. Välitalo1
1School of Pharmacy, University of Eastern Finland, Yliopistonranta 1 C, 70210, Kuopio, Finland

Tóm tắt

AbstractLack of data is an obvious limitation to what can be modelled. However, aggregate data in the form of means and possibly (co)variances, as well as previously published pharmacometric models, are often available. Being able to use all available data is desirable, and therefore this paper will outline several methods for using aggregate data as the basis of parameter estimation. The presented methods can be used for estimation of parameters from aggregate data, and as a computationally efficient alternative for the stochastic simulation and estimation procedure. They also allow for population PK/PD optimal design in the case when the data-generating model is different from the data-analytic model, a scenario for which no solutions have previously been available. Mathematical analysis and computational results confirm that the aggregate-data FO algorithm converges to the same estimates as the individual-data FO and yields near-identical standard errors when used in optimal design. The aggregate-data MC algorithm will asymptotically converge to the exactly correct parameter estimates if the data-generating model is the same as the data-analytic model. The performance of the aggregate-data methods were also compared to stochastic simulations and estimations (SSEs) when the data-generating model is different from the data-analytic model. The aggregate-data FO optimal design correctly predicted the sampling distributions of 200 models fitted to simulated datasets with the individual-data FO method. Graphic abstract

Từ khóa


Tài liệu tham khảo

Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445–479

Sheiner LB, Beal SL (1980) Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8:553–571

Sheiner BL, Beal SL (1981) Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 9:635–651

Sheiner LB, Beal SL (1983) Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 11:303–319

Weber S, Gelman A, Lee D et al (2018) Bayesian aggregation of average data: an application in drug development. Ann Appl Stat 12:1583–1604. https://doi.org/10.1214/17-AOAS1122

Mentre F, Mallet A, Baccar D (1997) Optimal design in random-effects regression models. Biometrika 84:429–442

Bauer RJ, Guzy S (2004) Monte carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic data. In: D’Argenio DZ (ed) Advanced methods of pharmacokinetic and pharmacodynamic systems analysis, vol 3. Springer, US, pp 135–163

Delyon B, Lavielle M, Moulines E (1999) Convergence of a stochastic approximation version of the EM algorithm. Ann Stat 27:94–128

Kuhn E, Lavielle M (2005) Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 49:1020–1038. https://doi.org/10.1016/j.csda.2004.07.002

Lavielle M (2014) Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools (1st ed.). Chapman and Hall/CRC. https://doi.org/10.1201/b17203

Jöreskog KG (1970) A general method for estimating a linear structural equation system*. ETS Res Bull Ser 1970:i–41. https://doi.org/10.1002/j.2333-8504.1970.tb00783.x

Retout S, Mentré F (2003) Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. J Biopharm Stat 13:209–227. https://doi.org/10.1081/BIP-120019267

Wang Y (2007) Derivation of various NONMEM estimation methods. J Pharmacokinet Pharmacodyn 34:575–593. https://doi.org/10.1007/s10928-007-9060-6

Riviere M-K, Ueckert S, Mentré F (2016) An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models. Biostat Oxf Engl 17:737–750. https://doi.org/10.1093/biostatistics/kxw020

Niederreiter H (1988) Low-discrepancy and low-dispersion sequences. J Number Theory 30:51–70. https://doi.org/10.1016/0022-314X(88)90025-X

Fidler M, Wilkins JJ, Hooijmaijers R et al (2019) Nonlinear mixed-effects model development and simulation using nlmixr and related R open-source packages. CPT Pharmacomet Syst Pharmacol 8:621–633. https://doi.org/10.1002/psp4.12445

Foracchia M, Hooker A, Vicini P, Ruggeri A (2004) POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 74:29–46. https://doi.org/10.1016/S0169-2607(03)00073-7

Nyberg J, Bazzoli C, Ogungbenro K et al (2015) Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies. Br J Clin Pharmacol 79:6–17. https://doi.org/10.1111/bcp.12352

Chenel M, Bouzom F, Aarons L, Ogungbenro K (2008) Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes. J Pharmacokinet Pharmacodyn 35:635–659. https://doi.org/10.1007/s10928-008-9104-6

Dumont C, Mentré F, Gaynor C et al (2013) Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information. Clin Pharmacokinet 52:43–57. https://doi.org/10.1007/s40262-012-0022-9

Thai H-T, Mazuir F, Cartot-Cotton S, Veyrat-Follet C (2015) Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel. Br J Clin Pharmacol 80:534–547. https://doi.org/10.1111/bcp.12702

Hooker AC, Foracchia M, Dodds MG, Vicini P (2003) An evaluation of population D-optimal designs via pharmacokinetic simulations. Ann Biomed Eng 31:98–111

Retout S, Duffull S, Mentré F (2001) Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed 65:141–151. https://doi.org/10.1016/s0169-2607(00)00117-6

Thông tin
Thông tin xuất bản

Journal of Pharmacokinetics and Pharmacodynamics

Tập 48 Số 5

623-638

Thông tin tác giả